Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Alan S. Coates, Binghe Xu, Andrew Tutt et al.|Annals of Oncology|2015Cited by 1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017Giuseppe Curigliano, Andrew Tutt, Harold J. Burstein et al.|Annals of Oncology|2017Cited by 1.3k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Harold J. Burstein, Binghe Xu, Giuseppe Curigliano et al.|Annals of Oncology|2021Cited by 799
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.Zefei Jiang, Hua Yang, Tao Sun et al.|Journal of Clinical Oncology|2022Cited by 36